{
  "question_stem": {
    "en": "An experiment is conducted to assess the effects of drug A on the hemodynamic actions of epinephrine. Two groups of healthy volunteers are selected. The first group receives only low-dose epinephrine, and its effects on diastolic blood pressure and heart rate are monitored and shown below (epinephrine group). The second group is pretreated with drug A and then infused with low-dose epinephrine to produce a new set of curves (epinephrine + drug A group) {{exhibit_1}}.",
    "zh": "进行一项实验以评估药物 A 对肾上腺素的血流动力学作用的影响。 选取两组健康志愿者。第一组仅接受低剂量肾上腺素，并监测其对舒张压和心率的影响，如下所示（肾上腺素组）。第二组预先用药 A 处理，然后静脉注射低剂量肾上腺素，以产生一组新的曲线（肾上腺素 + 药物 A 组） {{exhibit_1}}。"
  },
  "question": {
    "en": "Which of the following medications is most likely to be drug A?",
    "zh": "以下哪种药物最有可能为药物 A？"
  },
  "options": {
    "A": {
      "en": "Atropine",
      "zh": "阿托品"
    },
    "B": {
      "en": "Isoproterenol",
      "zh": "异丙肾上腺素"
    },
    "C": {
      "en": "Phentolamine",
      "zh": "酚妥拉明"
    },
    "D": {
      "en": "Phenylephrine",
      "zh": "苯肾上腺素"
    },
    "E": {
      "en": "Propranolol",
      "zh": "普萘洛尔"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "The hemodynamic actions of epinephrine occur secondary to agonistic effects at α1, β1, and β2 adrenoreceptors (relative strength: β1 = β2 > α1). Stimulation of β1 receptors in the heart increases cardiac rate and contractility, which increases systolic blood pressure due to the rise in cardiac output. Stimulation of β2 receptors in the skeletal muscle vasculature produces vasodilation and decreased diastolic blood pressure, while activation of α1 receptors on vascular smooth muscle in the skin and viscera increases peripheral resistance and raises diastolic blood pressure. At low doses, β2-mediated vasodilation predominates, whereas at high doses α1-induced vasoconstriction becomes more pronounced.\n\nIn this experiment, low-dose epinephrine by itself caused increased heart rate (β1 response) and decreased diastolic blood pressure (β2 response). However, after pretreatment with drug A, the heart rate fails to increase and there is a marked rise in diastolic blood pressure. These effects are best explained by pretreatment with a nonselective beta antagonist such as propranolol. When administered alone, propranolol produces peripheral vasoconstriction (β2 antagonism) without significantly increasing blood pressure (due to concomitant β1 blockade). However, in combination with epinephrine, propranolol will counteract epinephrine’s β2-mediated vasodilation and β1-mediated heart rate increase while leaving the α1 effect (vasoconstriction) intact. This will increase diastolic blood pressure and cause a slight reflexive reduction in heart rate.\n\n(Choice A) Atropine is a competitive antagonist of cholinergic muscarinic receptors in the heart (M2). Atropine increases the heart rate by blocking parasympathetic vagal influence; after pretreatment with atropine, epinephrine-mediated tachycardia would increase.\n\n(Choice B) Isoproterenol is a nonselective β-adrenergic agonist that stimulates both β2 receptors on vascular smooth muscle (leading to vasodilation) and cardiac β1 receptors (leading to increases in cardiac rate and contractility). A combination of isoproterenol and epinephrine would further decrease diastolic blood pressure and exacerbate the tachycardia.\n\n(Choice C) Phentolamine is a nonspecific alpha-1 and alpha-2 blocker with no beta-blocking effects that cause a profound fall in diastolic blood pressure and reflex tachycardia. If this were drug A, blood pressure would have decreased further in the pretreatment group and the rise in heart rate would have been exacerbated.\n\n(Choice D) Phenylephrine is a selective α-adrenergic agonist. Administration by itself may cause elevated systolic and diastolic blood pressures, which may be associated with reflex bradycardia. However, after pretreatment, epinephrine would still produce an initial rise in heart rate due to unopposed β1 stimulation.\n\nEducational objective: Epinephrine increases systolic blood pressure (α1 + β1) and heart rate (β1), and either increases or decreases diastolic blood pressure depending on the dose (either α1 or β2 predominates). Pretreatment with propranolol eliminates the β effects of epinephrine (vasodilation and tachycardia), leaving only the α effect (vasoconstriction).",
    "zh": "肾上腺素的血流动力学作用继发于对 α1、β1 和 β2 肾上腺素受体的激动作用（相对强度：β1 = β2 > α1）。刺激心脏中的 β1 受体可增加心率和收缩力，这会因心输出量增加而升高收缩压。刺激骨骼肌血管中的 β2 受体可产生血管舒张和降低舒张压，而激活皮肤和内脏血管平滑肌上的 α1 受体可增加外周阻力并升高舒张压。低剂量时，β2 介导的血管舒张占主导地位，而高剂量时，α1 诱导的血管收缩变得更加明显。\n\n在此实验中，低剂量肾上腺素本身会导致心率增加（β1 反应）和舒张压降低（β2 反应）。 然而，在用药物 A 预处理后，心率未能增加，舒张压显着升高。 这些影响最好用非选择性β受体拮抗剂（如普萘洛尔）的预处理来解释。 单独给药时，普萘洛尔会产生外周血管收缩（β2 拮抗作用），而不会显着增加血压（由于伴随的 β1 阻滞）。 然而，与肾上腺素联合使用时，普萘洛尔会抵消肾上腺素的 β2 介导的血管舒张和 β1 介导的心率增加，同时保留 α1 效应（血管收缩）。 这将增加舒张压并导致心率略有反射性降低。\n\n（选项 A）阿托品是心脏中胆碱能毒蕈碱受体 (M2) 的竞争性拮抗剂。 阿托品通过阻断副交感神经迷走神经的影响来增加心率；用阿托品预处理后，肾上腺素介导的心动过速会增加。\n\n（选项 B）异丙肾上腺素是一种非选择性 β 肾上腺素受体激动剂，可刺激血管平滑肌上的 β2 受体（导致血管舒张）和心脏 β1 受体（导致心率和收缩力增加）。 异丙肾上腺素和肾上腺素的组合将进一步降低舒张压并加剧心动过速。\n\n（选项 C）酚妥拉明是一种非特异性 α-1 和 α-2 阻滞剂，没有 β 阻滞作用，会导致舒张压急剧下降和反射性心动过速。 如果这是药物 A，预处理组的血压会进一步下降，心率升高会加剧。\n\n（选项 D）苯肾上腺素是一种选择性 α 肾上腺素受体激动剂。 单独给药可能会导致收缩压和舒张压升高，这可能与反射性心动过缓有关。 然而，在预处理后，由于不受阻的 β1 刺激，肾上腺素仍会产生最初的心率升高。\n\n教学目标：肾上腺素增加收缩压 (α1 + β1) 和心率 (β1)，并根据剂量增加或降低舒张压（α1 或 β2 占主导地位）。 用普萘洛尔预处理可消除肾上腺素的 β 效应（血管舒张和心动过速），仅留下 α 效应（血管收缩）。"
  },
  "summary": {
    "en": "This question tests knowledge of adrenergic receptor pharmacology and the effects of epinephrine and beta-blockers on heart rate and blood pressure. It requires understanding how different adrenergic receptors (alpha-1, beta-1, beta-2) mediate various cardiovascular effects and how a nonselective beta-blocker like propranolol can alter these effects.\n\nThe key to solving this question is to analyze the changes in heart rate and diastolic blood pressure after pretreatment with drug A. The fact that heart rate fails to increase and diastolic blood pressure rises suggests that the beta-adrenergic effects of epinephrine (beta-1 mediated increase in heart rate and beta-2 mediated decrease in diastolic blood pressure) are being blocked, leaving the alpha-1 mediated vasoconstriction unopposed.",
    "zh": "此题考察对肾上腺素受体药理学的了解以及肾上腺素和β受体阻滞剂对心率和血压的影响。 它需要了解不同的肾上腺素受体（α-1、β-1、β-2）如何介导各种心血管效应，以及普萘洛尔等非选择性β受体阻滞剂如何改变这些效应。\n\n解决此问题的关键是分析用药物 A 预处理后心率和舒张压的变化。心率未能增加和舒张压升高这一事实表明，肾上腺素的β肾上腺素能效应（β-1 介导的心率增加和β-2 介导的舒张压降低）被阻断，留下α-1 介导的血管收缩不受阻。"
  },
  "tags": "Adrenergic receptors; Epinephrine; Propranolol; Beta-blockers; Cardiovascular pharmacology; Sympathomimetic agents; Heart rate; Blood pressure; Vasoconstriction; Vasodilation",
  "category": "CVS",
  "question_id": "1364",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\1364",
  "extracted_at": "2025-11-05T11:53:02.292663",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:45:04.510452",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}